129 related articles for article (PubMed ID: 20471842)
1. Design and synthesis of new anticancer pyrimidines with multiple-kinase inhibitory effect.
El-Deeb IM; Lee SH
Bioorg Med Chem; 2010 Jun; 18(11):3860-74. PubMed ID: 20471842
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of new potent anticancer pyrazoles with high FLT3 kinase inhibitory selectivity.
El-Deeb IM; Lee SH
Bioorg Med Chem; 2010 Jun; 18(11):3961-73. PubMed ID: 20472440
[TBL] [Abstract][Full Text] [Related]
3. Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
Puttini M; Redaelli S; Moretti L; Brussolo S; Gunby RH; Mologni L; Marchesi E; Cleris L; Donella-Deana A; Drueckes P; Sala E; Lucchini V; Kubbutat M; Formelli F; Zambon A; Scapozza L; Gambacorti-Passerini C
Haematologica; 2008 May; 93(5):653-61. PubMed ID: 18367480
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor.
Park BS; El-Deeb IM; Yoo KH; Oh CH; Cho SJ; Han DK; Lee HS; Lee JY; Lee SH
Bioorg Med Chem Lett; 2009 Aug; 19(16):4720-3. PubMed ID: 19596575
[TBL] [Abstract][Full Text] [Related]
5. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.
Santucci MA; Corradi V; Mancini M; Manetti F; Radi M; Schenone S; Botta M
ChemMedChem; 2009 Jan; 4(1):118-26. PubMed ID: 19039816
[TBL] [Abstract][Full Text] [Related]
6. Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Shallal HM; Russu WA
Eur J Med Chem; 2011 Jun; 46(6):2043-57. PubMed ID: 21429632
[TBL] [Abstract][Full Text] [Related]
7. Identification of 5,6-substituted 4-aminothieno[2,3-d]pyrimidines as LIMK1 inhibitors.
Sleebs BE; Nikolakopoulos G; Street IP; Falk H; Baell JB
Bioorg Med Chem Lett; 2011 Oct; 21(19):5992-4. PubMed ID: 21852129
[TBL] [Abstract][Full Text] [Related]
8. Identification of potent c-Src inhibitors strongly affecting the proliferation of human neuroblastoma cells.
Radi M; Brullo C; Crespan E; Tintori C; Musumeci F; Biava M; Schenone S; Dreassi E; Zamperini C; Maga G; Pagano D; Angelucci A; Bologna M; Botta M
Bioorg Med Chem Lett; 2011 Oct; 21(19):5928-33. PubMed ID: 21856155
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of novel 2,4'-bis substituted diphenylamines as anticancer agents and potential epidermal growth factor receptor tyrosine kinase inhibitors.
Abou-Seri SM
Eur J Med Chem; 2010 Sep; 45(9):4113-21. PubMed ID: 20580136
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and docking study of 2-phenylaminopyrimidine Abl tyrosine kinase inhibitors.
Lü S; Luo Q; Hao X; Li X; Ji L; Zheng W; Wang F
Bioorg Med Chem Lett; 2011 Dec; 21(23):6964-8. PubMed ID: 22033461
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, biological evaluation and docking studies of 4-amino substituted 1H-pyrazolo[3,4-d]pyrimidines.
Schenone S; Brullo C; Bruno O; Bondavalli F; Mosti L; Maga G; Crespan E; Carraro F; Manetti F; Tintori C; Botta M
Eur J Med Chem; 2008 Dec; 43(12):2665-76. PubMed ID: 18342402
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, in-vitro antiproliferative activity and kinase profile of new picolinamide based 2-amido and ureido quinoline derivatives.
El-Damasy AK; Seo SH; Cho NC; Kang SB; Pae AN; Kim KS; Keum G
Eur J Med Chem; 2015 Aug; 101():754-68. PubMed ID: 26218653
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and cytotoxic activity of 2-methylimidazo[1,2-a]pyridine- and quinoline-substituted 2-aminopyrimidine derivatives.
Vilchis-Reyes MA; Zentella A; Martínez-Urbina MA; Guzmán A; Vargas O; Ramírez Apan MT; Ventura Gallegos JL; Díaz E
Eur J Med Chem; 2010 Jan; 45(1):379-86. PubMed ID: 19879023
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of cyclin D1-CDK4: synthesis, biological evaluation and structure-activity relationships. Part 2.
Horiuchi T; Nagata M; Kitagawa M; Akahane K; Uoto K
Bioorg Med Chem; 2009 Dec; 17(23):7850-60. PubMed ID: 19889545
[TBL] [Abstract][Full Text] [Related]
15. 2-Anilino-4-(benzimidazol-2-yl)pyrimidines--a multikinase inhibitor scaffold with antiproliferative activity toward cancer cell lines.
Determann R; Dreher J; Baumann K; Preu L; Jones PG; Totzke F; Schächtele C; Kubbutat MH; Kunick C
Eur J Med Chem; 2012 Jul; 53():254-63. PubMed ID: 22560627
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents.
Cai J; Sun M; Wu X; Chen J; Wang P; Zong X; Ji M
Eur J Med Chem; 2013 May; 63():702-12. PubMed ID: 23567960
[TBL] [Abstract][Full Text] [Related]
17. Development of pyridopyrimidines as potent Akt1/2 inhibitors.
Wu Z; Hartnett JC; Neilson LA; Robinson RG; Fu S; Barnett SF; Defeo-Jones D; Jones RE; Kral AM; Huber HE; Hartman GD; Bilodeau MT
Bioorg Med Chem Lett; 2008 Feb; 18(4):1274-9. PubMed ID: 18249537
[TBL] [Abstract][Full Text] [Related]
18. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.
Traxler P; Bold G; Frei J; Lang M; Lydon N; Mett H; Buchdunger E; Meyer T; Mueller M; Furet P
J Med Chem; 1997 Oct; 40(22):3601-16. PubMed ID: 9357527
[TBL] [Abstract][Full Text] [Related]
19. N-[2-Methyl-5-(triazol-1-yl)phenyl]pyrimidin-2-amine as a scaffold for the synthesis of inhibitors of Bcr-Abl.
Arioli F; Borrelli S; Colombo F; Falchi F; Filippi I; Crespan E; Naldini A; Scalia G; Silvani A; Maga G; Carraro F; Botta M; Passarella D
ChemMedChem; 2011 Nov; 6(11):2009-18. PubMed ID: 21990039
[TBL] [Abstract][Full Text] [Related]
20. 3D QSAR models built on structure-based alignments of Abl tyrosine kinase inhibitors.
Falchi F; Manetti F; Carraro F; Naldini A; Maga G; Crespan E; Schenone S; Bruno O; Brullo C; Botta M
ChemMedChem; 2009 Jun; 4(6):976-87. PubMed ID: 19326384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
